Dasatinib restores full donor chimerism in a patient with imatinib-resistant Ph+ ALL relapsing after unrelated cord blood transplantation [1]

Leukemia and Lymphoma

Volumn 48, Issue 10, 2007, Pages 2054-2057

  Reddiconto, Giovanni ^a   Chiusolo, Patrizia ^a   Fiorini, Alessia ^a   Farina, Giuliana ^a   Sorà, Federica ^a   Leone, Giuseppe ^a   Sica, Simona ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DASATINIB; DAUNORUBICIN; DIURETIC AGENT; FOSCARNET; GANCICLOVIR; IMATINIB; INFLIXIMAB; METHOTREXATE; NILOTINIB; PREDNISONE; STEROID; THYMOCYTE ANTIBODY; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; BONE MARROW BIOPSY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CASE REPORT; CHIMERA; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS INFECTION; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; DRUG DOSE ESCALATION; FEMALE; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; LETTER; LEUKEMIA RELAPSE; NAUSEA; PHILADELPHIA 1 CHROMOSOME; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; UNSPECIFIED SIDE EFFECT;

ADULT; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHIMERISM; CORD BLOOD STEM CELL TRANSPLANTATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECURRENCE; REMISSION INDUCTION; THIAZOLES; TIME FACTORS;

EID: 35148848290     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701549570     Document Type: Letter

References (11)

1. Faderl, S., Kantarjian, H. M., Thomas, D. A., Cortes, J., Giles, F. and Pierce, S. (2000) Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma, 36, pp. 263-273.
2. Cornelissen, J. J., Carston, M., Kollman, C., King, R., Dekker, A. W. and Lowenberg, B. (2001) Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: Strong graft-versus-leukemia effect and risk factors determining outcome. Blood, 97, pp. 1572-1577.
3. Lee, K. H., Lee, J. H., Choi, S. J., Lee, J. H., Seol, M. and Lee, Y. S. (2005) Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia, 19, pp. 1509-1516.
4. Hofmann, W. K., Komor, M., Hoelzer, D. and Ottmann, O. G. (2004) Mechanisms of resistance to STI571 (imatinib) in Philadelphia-chromosome positive acute leukemia lymphoblastic leukemia. Leuk Lymphoma, 45, pp. 655-660.
5. O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W. and Mestan, J. (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res, 65, pp. 4500-4505.
6. Cortes, J., Rousselot, P., Kim, D. W., Ritchie, E., Hamerschlak, N. and Coutre, S. (2007) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 109, pp. 3207-3213.
7. Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J. and Paquette, R. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med, 354, pp. 2531-2541.
8. Thiede, C., Bornhauser, M. and Ehninger, G. (2004) Evaluation of STR informativity for chimerism testing - comparative analysis of 27 STR systems in 203 matched related donor recipient pairs. Leukemia, 18, pp. 248-254.
9. Jabbour, E., Cortes, J., Kantarjian, H., Giralt, S., Jones, D. and Jones, R. (2006) Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood, 108, pp. 1421-1423.
10. Dompret, H., Ottmann, O. G., Rosti, G., Simonsson, B., Larson, R. A. and Gollerker, A. (2006) Dasatinib (SPRYCEL) in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who are imatinib-resistant or -intolerant: Updated results from the CA180-015 'START-L' study. ASH Annual Meeting Abstracts, 108, p. 286.
11. Shimoni, A., Kroger, N., Zander, A. R., Rowe, J. M., Hardan, I. and Avigdor, A. (2003) Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia, 17, pp. 290-297.